Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.70 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | UNG | P13051 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902633 | 0.90 | ALDH1A1 (0.55) | ALDH1A1CYP2A6TRIM24TRIM33UNG | |
| SCHEMBL1664238 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CYP2A6TRIM24TRIM33UNG | |
| SCHEMBL5446914 | 0.84 | ALDH1A1 (0.60) | ALDH1A1CYP2A6TRIM24TRIM33UNG | |
| Benzaldehyde SCHEMBL6334311 | 0.84 | ALDH1A1 (0.88) | ALDH1A1CYP2A6TRIM24TRIM33UNG | |
| Benzaldehyde SCHEMBL9236967 | 0.84 | — | — | |
| Benzaldehyde SCHEMBL896024 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP2A6UNGLMNATRPA1 | |
| Benzaldehyde SCHEMBL573 | 0.84 | — | — | |
| Benzaldehyde SCHEMBL22400699 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP2A6UNGLMNATRPA1 | |
| Benzaldehyde SCHEMBL1330097 | 0.84 | — | — | |
| Benzaldehyde SCHEMBL10051945 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103665202-B | A kind of olefin polymerization catalyst components and its preparation method and application | SINOPEC CORP. (CN) | 2015-08-19 | — | — | CN | claimed |
| CN-103665202-A | Olefin polymerization catalyst component as well as preparation method and application thereof | CHINA PETROLEUM & CHEMICAL | 2014-03-26 | — | — | CN | claimed |
| CN-114456217-A | Synthetic method of glycal compound | 江西科技师范大学 | 2022-05-10 | — | — | CN | disclosed |
| CN-107245064-B | The preparation method of Suo Feibuwei intermediate | 福安药业集团宁波天衡制药有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-107531657-B | Two substitution -2- deoxidation -2- hydroxy-2-methyl of (2S, 3R, 4R) -3,5--D-ribose-gamma lactone Preparation Method And Their Intermediate | 苏州旺山旺水生物医药有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-109438397-A | A kind of synthetic method of the intermediate of Suo Feibuwei | 江苏科本药业有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109438537-A | A kind of preparation method of Suo Feibuwei key intermediate | 江苏科本药业有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109152791-A | The method of -2 ' of the fluoro- 5- azepine of 2 ', 2 '-two-deoxycytidine or its prodrug treatment TP53 wild type tumor | 表观遗传学药业有限责任公司 | 2019-01-04 | — | — | CN | disclosed |
| US-10030043-B2 | Method for the synthesis of clofarabine | SYNBIAS PHARMA AG (CH) | 2018-07-24 | — | — | US | disclosed |
| EP-3134537-B1 | METHOD FOR THE SYNTHESIS OF CLOFARABINE | SYNBIAS PHARMA AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| EP-3134537-A1 | METHOD FOR THE SYNTHESIS OF CLOFARABINE | Synbias Pharma AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0301908-B1 | 1-(3,5-Di-0-benzoyl-2-deoxy-beta-D-threo-pentofuranosyl)thymine and the method of producing the same | CESKOSLOVENSKA AKADEMIE VED (CS) | 1994-02-09 | — | — | EP | disclosed |
| EP-0577302-A1 | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5256798-A | Treating beta-anomer ribofuranosyl sulfonate with source of conjugate anion | ELI LILLY AND COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0301908-A2 | 1-(3,5-Di-0-benzoyl-2-deoxy-beta-D-threo-pentofuranosyl)thymine and the method of producing the same | Ceskoslovenska akademie ved (CS) | 1989-02-01 | — | — | EP | disclosed |
| US-3998807-A | ARABINOFURANOSYL CYTOSINES AND METHODS OF MAKING | SYNTEX (U.S.A.) INC. (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030043-B2 | Method for the synthesis of clofarabine | PFAS, SAMHD1, MTAP | ALDH1A1 1131/4885CYP2A6 191/4885TRIM24 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.